Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baclofen is a small molecule skeletal muscle relaxant and antispasmodic agent, primarily used to treat spasticity associated with multiple sclerosis, spinal cord injury, or other spinal cord diseases. It acts as a specific agonist at the gamma-Aminobutyric acid type B receptor (GABA-B receptor), reducing excitatory neurotransmission in the central nervous system. This leads to decreased muscle spasms, cramping, and tightness. While originally developed for epilepsy, its main clinical use is now for severe spasticity of cerebral or spinal origin in both adults and children over 12 years old. It may also be used off-label for alcohol use disorder and opioid withdrawal symptoms[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on baclofen.